Pharma Giants Defy Patent Cliff Worries with Diversified Pipelines

Four pharmaceutical giants have proven resilient in the face of patent cliffs, maintaining their dividend payouts despite losing exclusivity on certain blockbuster products. Johnson & Johnson (JNJ) has a particularly impressive track record, having raised its quarterly payout to $1.34 per share, marking its 64th consecutive year of annual increases.

With a current share price of $268.95 and an annualized forward dividend of $5.36 per share, J&J's dividend safety is among the strongest in large-cap pharma. Management has reaffirmed that it is on track to generate full-year 2026 free cash flow approaching $21 billion.

Pfizer (PFE) offers a higher yield at 6.14%, but its payout coverage looks less secure due to an impending loss-of-exclusivity wave on several of its top-selling products, including Eliquis and Ibrance. Merck (MRK) boasts the strongest oncology franchise in the sector and has raised its quarterly dividend to $0.85 per share.

Bristol Myers Squibb (BMY), with a 94-year history of continuous dividend payments, is another stalwart in this group. Its growth portfolio finally appears big enough to matter, with sales rising 14% in Q2 and nearly 60% of total revenue coming from growth-platform products.

All four companies have reaffirmed their commitment to maintaining their dividend payouts, with management teams citing diversified pipelines and cash generation as evidence of their ability to withstand patent cliffs.